Article thumbnail

Evaluation of biological agents targeted at early-stage disease

By Marta Guix, Ingrid A Mayer, Ingrid M Meszoely and Carlos L Arteaga
Topics: Short Communication
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2008). A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefitinib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) breast cancer (MBC). Proc Am Soc Clin Oncol
  2. (2007). A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.
  3. (2006). Ali S: Phosphorylation of ERalpha at serine 118 in primary breastPage
  4. (2006). AR: Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.
  5. (2005). Chang JC: Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.
  6. (2008). CL: Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
  7. (2000). E: Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. Clin Cancer Res
  8. (2005). Efficacy and tolerability of gefitinib in oestrogen receptor negative and tamoxifen resistant oestrogen receptor positive locally advanced or metastatic breast cancer. Breast Cancer Res Treat
  9. (2007). EP: TBCRC 001: EGFR inhibition with cetuximab in metastatic triple negative (basallike) breast cancer [abstract 307]. Breast Cancer Res Treat
  10. Hargreaves: Randomized phase II study of gefitinib (IRESSA) or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancer [abstract 2067]. Breast Cancer Res Treat 2007, 106(suppl 1):S107.
  11. (2005). IE: Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer—a study from the IMPACT trialists.
  12. (2001). Muchmore DB: Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev
  13. (2007). RC: Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol
  14. (2003). Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat
  15. (2005). Tobias JS: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet
  16. (1994). Wakeling AE: Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.